▼ 1.13%
prev close
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-02-16 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1237d ago | — | |
| 2022-11-01 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1324d ago | — |
2023-02-16
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1237d ago
2022-11-01
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1324d ago
Recent News
Powered by Polygon.io
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Trade Timeline
Congressional activity, newest first
Virginia Foxx
2023-02-16 · Purchase
$1,001 - $15,000
Virginia Foxx
2022-11-01 · Purchase
$1,001 - $15,000